LLY
Still in the game
Eli Lilly is back with another reminder that the GLP-1 party may still have room at the table. Its oral GLP-1, Foundayo (orforglipron), showed cardiovascular safety in its largest and longest type 2 diabetes study while also delivering sustained A1C reduction and weight loss.
Why investors care
That matters because the GLP-1 market is basically pharmaceutical’s version of a heavyweight title fight. If Lilly can prove an oral drug can be safe, effective, and convenient, it gets a lot harder for rivals to push back on the company’s long-term diabetes and obesity moat.
- The study was described as Lilly’s largest and longest type 2 diabetes readout for the drug.
- The key takeaway wasn’t just “it works,” but “it keeps working” without raising a cardiovascular red flag.
- Oral delivery is the cherry on top: pills are a lot easier to swallow, literally and strategically, than injections.
Big picture
This doesn’t mean the finish line is crossed, but it does keep the market’s expectations pointed in the same direction: higher. For Lilly, every positive readout makes the GLP-1 empire look a little less like hype and a little more like infrastructure. Big picture: investors don’t just want a good drug — they want a category king, and Lilly is still acting like one.